Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David Guyer
AddedMar 31, 2024
UpdatedMay 31, 2026
David Guyer

David Guyer

Board Member, Visus Therapeutics

Crunchbase

David Guyer's Career

Visus Therapeutics
Visus Therapeutics

Seattle, WA, US

Board Member· Board
Imagen Biotech
Imagen Biotech

New York City, NY, US

Board Member· Board
AlloCure
AlloCure

Burlington, MA, US

Board Member· Board
Lux Biosciences
Lux Biosciences

Jersey City, NJ, US

Board Member· Board
Neovista
Neovista

Newark, CA, US

Board Member· Board
PanOptica
PanOptica

Mount Arlington, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David Guyer's Career

Visus Therapeutics
Visus Therapeutics
Series B$56M452019Seattle, WA, US
Board Member· Board

Leadership at Visus Therapeutics

Sam LanyonSam LanyonBoard Member
Ben BergoBen BergoBoard Member
John De KoningJohn De KoningBoard Member
Imagen Biotech
Imagen Biotech
Series A$40M302011New York City, NY, US
Board Member· Board

Leadership at Imagen Biotech

Matthew FeinsodMatthew FeinsodCo-Founder
Gene HillGene HillBoard Member

Similar to Imagen Biotech

Aurion BiotechAurion BiotechSeattle, WA, USBiotech, Therapiesest. 2021Aurion BiotechSeattle, WA, US · est. 2021

Aurion Biotech: Clinical-stage biotech firm pioneering advanced therapies to cure blindness.

Late Stage Private · $120M55
Qlaris BioQlaris BioWellesley, MA, USTherapeuticsest. 2019Qlaris BioWellesley, MA, US · est. 2019

Therapeutics firm focusing on high-need areas in debilitating eye diseases.

Series A · $25M9
VisioxVisioxTarrytown, NY, USTherapeuticsest. 2022VisioxTarrytown, NY, US · est. 2022

Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.

Seed · $7M7
Empire BiotechnologiesEmpire BiotechnologiesSan Francisco, CA, USTherapeuticsest. 2013Empire BiotechnologiesSan Francisco, CA, US · est. 2013

Empire Biotechnologies: Innovating therapies for unmet medical needs, focusing on malabsorption diseases.

Pre-Seed · $1.1M1
AlloCure
AlloCure
Series B$47M112008Burlington, MA, US
Board Member· Board

Leadership at AlloCure

Mette Kirstine AggerMette Kirstine AggerBoard Member
John WirthlinJohn WirthlinFounder
Thomas DyrbergThomas DyrbergBoard Member
Greg MaddenGreg MaddenBoard Member

Similar to AlloCure

Alloplex BiotherapeuticsAlloplex BiotherapeuticsBoston, MA, USCellular Therapiesest. 2016Alloplex BiotherapeuticsBoston, MA, US · est. 2016

Alloplex Biotherapeutics, a Boston-based firm, develops broad-spectrum, tumor-agnostic cellular therapies.

Series A · $21.2M5
Platelet BioGenesisPlatelet BioGenesisWatertown, MA, USCell Therapyest. 2014Platelet BioGenesisWatertown, MA, US · est. 2014

US-based PlateletBio pioneers in allogeneic cell therapy, innovating superior solutions for unmet medical challenges.

Series B · $132.1M39
Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
Orca BioOrca BioMenlo Park, CA, USCell Therapyest. 2016Orca BioMenlo Park, CA, US · est. 2016

Orca Bio: A clinical-stage cell therapy firm innovating curative treatments for over 100 diseases.

Series D · $192M124
Lux Biosciences
Lux Biosciences
Acquired$129.2M02005Jersey City, NJ, US
Board Member· Board

Leadership at Lux Biosciences

Axel BolteAxel BolteBoard Member
Paul ChaneyPaul ChaneyBoard Member
David SchnellDavid SchnellBoard Member
Dr Lutz B GiebelDr Lutz B GiebelBoard Member

Similar to Lux Biosciences

VisioxVisioxTarrytown, NY, USTherapeuticsest. 2022VisioxTarrytown, NY, US · est. 2022

Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.

Seed · $7M7
Qlaris BioQlaris BioWellesley, MA, USTherapeuticsest. 2019Qlaris BioWellesley, MA, US · est. 2019

Therapeutics firm focusing on high-need areas in debilitating eye diseases.

Series A · $25M9
Aurion BiotechAurion BiotechSeattle, WA, USBiotech, Therapiesest. 2021Aurion BiotechSeattle, WA, US · est. 2021

Aurion Biotech: Clinical-stage biotech firm pioneering advanced therapies to cure blindness.

Late Stage Private · $120M55
Ocular ScienceOcular ScienceManhattan Beach, CA, USEye Care Productsest. 2015Ocular ScienceManhattan Beach, CA, US · est. 2015

Ocular Science®: A leading biotech firm innovating affordable eye care solutions.

Seed · $175.1k46
Neovista
Neovista
Series A$156.9M142002Newark, CA, US
Board Member· Board

Leadership at Neovista

Charles LarsenCharles LarsenFounder
Ryan SchwarzRyan SchwarzBoard Member
David GyorkeDavid GyorkeBoard Member
Bill GreeneBill GreeneBoard Member
Stephen M Martin \"Steve\"Stephen M Martin \"Steve\"Board Member
Gerard Van Hamel PlaterinkGerard Van Hamel PlaterinkBoard Member
PanOptica
PanOptica
Acquired$109.9M02009Mount Arlington, NJ, US
Board Member· Board

Leadership at PanOptica

Colin GoddardColin GoddardBoard Member
Kevin StarrKevin StarrBoard Member
Tracy M SaxtonTracy M SaxtonBoard Member
Bruce PeacockBruce PeacockBoard Member
Lutz GiebelLutz GiebelBoard Member

Similar to PanOptica

Hyperion DeFiHyperion DeFiNew York City, NY, USTherapeuticsest. 2014Hyperion DeFiNew York City, NY, US · est. 2014

Eyenovia, Inc.: A NASDAQ-listed biopharmaceutical firm innovating advanced ophthalmic therapeutics.

Public · $75.1M41
Ocular TherapeutixOcular TherapeutixBedford, MA, USOphthalmic Therapiesest. 2006Ocular TherapeutixBedford, MA, US · est. 2006

Ocular Therapeutix, Inc.: Global biopharma innovator in hydrogel-based ophthalmic therapies.

Public · $386.5M274
EyeCyteEyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5
VisioxVisioxTarrytown, NY, USTherapeuticsest. 2022VisioxTarrytown, NY, US · est. 2022

Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.

Seed · $7M7

David Guyer's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to David Guyer

Mike RossMike RossBoard Member · Therini BioMichael RoweMichael RoweBoard Member · Hyperion DeFiBrad WebbBrad WebbBoard Member · NuMediiDavid GellerDavid GellerCEO · EyejotRobert Edward GrantRobert Edward GrantBoard Member · ReShape MedicalJay CormierJay CormierCo-Founder · Eyedaptic